Site Search

 Poll
Which Gaming System Do You Prefer?
Cast your vote

Getting Poll Results
LONDON (Reuters) - GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its presence in oncology, its new head of pharmaceuticals told Reuters. . . more
ZURICH (Reuters) - Combining Roche's Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients, the Swiss drugmaker said on Monday . . more
JAKARTA (Reuters) - Health authorities in Jakarta kicked off a special immunization program on Monday to rein in an "extraordinary" outbreak of diphtheria that has sparked concerns about the Indonesian capitals readiness to host the Asian Games next June. Diphtheria cases have spiked 42 percent since last year, health officials say, with at least 32 deaths and more than 590 cases recorded across the archipelago, the bulk of them in densely populated Jakarta and neighboring provinces. . . more
LOS ANGELES (Reuters) - Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. . . more
MANILA (Reuters) - As she announced in January 2016 that the Philippines would immunize one million children with a new dengue vaccine, the nation's then health secretary Janette Garin boasted it was a world-first and a tribute to her country's "expertise" in research. . . more
NEW YORK (Reuters) - Ascension Health and Providence St. Joseph Health are in talks about a merger between the two Catholic non-profits that would create the largest U.S. hospital chain, the Wall Street Journal reported on Sunday, citing people familiar with the discussions. . . more
(Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday. . . more
(Reuters) - Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a medical meeting on Sunday. . . more
(Reuters) - An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on Sunday. . . more
(Reuters) - More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday. . . more


Free Online Games from NickeySurf.com